GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ( "the Company" or "Nxera". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report can be found here.
Neurocrine ( NBIX ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, July 30, 2025 at 8:30 p.m. ETChief Executive Officer - Kyle J. GanoContinue reading ...
Neurocrine ( NBIX ) Q2 Revenue Jumps 17%
Neurocrine Biosciences ( NASDAQ:NBIX ) , a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report revealed substantial outperformance: Non-GAAP diluted earnings per share reached $1.65, topping ...
Neurocrine Biosciences ( NBIX ) Q2 Earnings and Revenues Beat Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Indivior PLC ( INDV ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Indivior (INDV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences ( NBIX ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant ...
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical ( CPRX Quick QuoteCPRX - ) and Neurocrine Biosciences ( NBIX Quick QuoteNBIX - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF ( FBT ) ?
Sector ETF report for ...
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations - NetraMark Holdings ( OTC:AINMF )
TORONTO, June 12, 2025 ( GLOBE NEWSWIRE ) -- NetraMark Holdings Inc. ( the "Company" or "NetraMark" ) AIAI AINMF PF, an artificial intelligence ( AI ) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered ...
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
TORONTO, June 12, 2025 ( GLOBE NEWSWIRE ) -- NetraMark Holdings Inc. ( the "Company" or "NetraMark" ) ( CSE: AIAI ) ( OTCQB: AINMF ) ( Frankfurt: PF0 ) , an artificial intelligence ( AI ) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined ...
Should You Invest in the SPDR S&P Biotech ETF ( XBI ) ?
Sector ETF report for ...
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W.
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional ...
CPRX or NBIX: Which Is the Better Value Stock Right Now?
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) today announces that its partner, Neurocrine Biosciences ( "Neurocrine" ) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 ( NBI-'568 ) as a potential ...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - Neurocrine Biosciences ( NASDAQ:NBIX ) , Fate Therapeutics ( NASDAQ:FATE )
SAN DIEGO, May 30, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. FATE, a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell ( iPSC ) -derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew ...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
SAN DIEGO, May 30, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( NASDAQ: FATE ) , a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell ( iPSC ) -derived off-the-shelf cellular immunotherapies to patients, today announced the ...
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
Tokyo, Japan and Cambridge, UK, 29 May 2025 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of ...
Should You Invest in the Invesco Biotechnology & Genome ETF ( PBE ) ?
Sector ETF report for ...
Is Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Neurocrine Biosciences ( NASDAQ:NBIX )
A large exercise of company stock options by CHARLES KEVIN GORMAN, Board Member at Neurocrine Biosciences NBIX was disclosed in a new SEC filing on May 22, as part of an insider exercise. What Happened: A Form 4 filing from the U.S.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., May 15, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase ( ALPL ) to ...
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
LEXINGTON, Mass., May 15, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline ...
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Should Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) Be on Your Investing Radar?
Style Box ETF report for ...
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Neurocrine Biosciences ( NASDAQ:NBIX )
Q1 adjusted EPS was 70 cents, beating the $0.54 consensus despite falling year-over-year. Ingrezza Q1 net sales hit $545 million, up 8% YoY, with record new patient starts reported. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday - Aramark ( NYSE:ARMK ) , Ameresco ( NYSE:AMRC )
U.S. stocks were lower, with the Nasdaq Composite falling over 1% on Tuesday. Shares of FARO Technologies, Inc. FARO rose sharply during Tuesday's session after the company announced it entered into a definitive agreement to be acquired by AMETEK for an enterprise value of approximately $920 ...
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Neurocrine Biosciences ( NBIX ) Q1 Earnings Miss Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -81.40% and 2.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ( "the Company" or "Nxera". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found here.
Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
Tokyo, Japan and Cambridge, UK, 1 May 2025 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) today announces that its partner Neurocrine Biosciences Inc. ( "Neurocrine" ) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568 ...
Zoetis ( ZTS ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of ...
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - Voyager Therapeutics ( NASDAQ:VYGR )
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -
Neurocrine Biosciences ( NBIX ) Q1 Earnings Preview: What's in the Cards?
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday - Expand Energy ( NASDAQ:EXE ) , Autoliv ( NYSE:ALV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Dan Levy upgraded the rating for Autoliv, Inc.
Implied Volatility Surging for Neurocrine Biosciences ( NBIX ) Stock Options
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - Voyager Therapeutics ( NASDAQ:VYGR )
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the ...
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study ...
Is Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Hyku Biosciences Appoints Keith Wilcoxen, PhD, as Chief Scientific Officer
BURLINGTON, Mass., March 19, 2025 ( GLOBE NEWSWIRE ) -- Hyku Biosciences, a pioneer in precision medicine, today announced the appointment of Keith Wilcoxen, PhD, as Chief Scientific Officer. Dr. Wilcoxen has more than 25 years of experience advancing new therapies through preclinical and early ...
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Company to host conference call and webcast today, March 13th ...
Should Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) Be on Your Investing Radar?
Style Box ETF report for ...
